Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis

por Iskandar, I.Y.K., Ashcroft, D.M., Warren, R.B., Lunt, M., McElhone, K., Smith, C.H., Reynolds, N.J., Griffiths, C.E.M.
Publicado 2017

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

por Rungapiromnan, W., Mason, K.J., Lunt, M., McElhone, K., Burden, A.D., Rutter, M.K., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Publicado 2019

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

por Yiu, Z.Z.N., Mason, K.J., Barker, J.N.W.N., Hampton, P.J., McElhone, K., Smith, C.H., Warren, R.B., Griffiths, C.E.M., Lunt, M., Burden, A.D.
Publicado 2019

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermato...

por Yiu, Z.Z.N., Ashcroft, D.M., Evans, I., McElhone, K., Lunt, M., Smith, C.H., Walton, S., Murphy, R., Reynolds, N.J., Ormerod, A.D., Griffiths, C.E.M., Warren, R.B.
Publicado 2018

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review

por Mason, K.J., Williams, S., Yiu, Z.Z.N., McElhone, K., Ashcroft, D.M., Kleyn, C.E., Jabbar‐Lopez, Z.K., Owen, C.M., Reynolds, N.J., Smith, C.H., Wilson, N., Warren, R.B., Griffiths, C.E.M.
Publicado 2019